Roche, its Genentech subsidiary and an independent Russian distributor cannot be sued in the United States for actions they allegedly took in Russia in order to block a competitor from entering the US market for biosimilar cancer-treatment drugs, a federal appeals court held on Tuesday (November 5).
The 2nd US Circuit Court of Appeals rejected Russian pharmaceutical company Biocad JSC’s argument that federal and state antitrust laws are broad enough to cover foreign conduct that is ultimately intended to affect US imports.
The suit was filed by Biocad JSC, which makes off-brand versions of cancer medications on which Roche’s patents will soon expire. Biocad also targeted Russian drug distributor R-Pharm JSC and Roche subsidiaries Genentech Inc. and F. Hoffman-La Roche.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI